The Copenhagen Actinic Keratosis Study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field-directed topical treatment with cytosolic phospholipase A2 inhibitor, AVX001, in participants with actinic keratosis: protocol for a randomised controlled phase I/IIa trial

The Copenhagen Actinic Keratosis Study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field-directed topical treatment with cytosolic phospholipase A2 inhibitor, AVX001, in participants with actinic keratosis: protocol for a randomised controlled phase I/IIa trial

Introduction Actinic keratosis (AK) is the most common precancerous skin condition caused by long-term UV exposure. Given the high recurrence rate of 15%–53%, identifying safe and effective treatment options is warranted. AVX001, a cytosolic phospholipase A2α (cPLA2α) enzyme inhibitor, is a novel an...

Full description

Bibliographic Details
Main Authors: Merete Haedersdal, Kim Kilov, Vinzent Kevin Ortner, Berit Johansen, Alejandro Castillo Mondragón, Tore Duvold, Jesper Kihl, Felicity J Ashcroft, Astrid J Feuerherm, Charlotte Pind Laugesen, Maiken Lise Marcker Espersen, Ionela Manole, Ari Pall Isberg, Anders Daniel Andersen, Elin Rakvaag, John R Zibert
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/10/e061012.full

Internet

https://bmjopen.bmj.com/content/12/10/e061012.full

Similar Items